Loading...
CDLX logo

Cardlytics, Inc.Informe acción NasdaqGM:CDLX

Capitalización bursátil US$38.1m
Precio de las acciones
US$0.72
US$1.04
30.5% infravalorado descuento intrínseco
1Y-61.5%
7D20.9%
1D
Valor de la cartera
Ver

Cardlytics, Inc.

Informe acción NasdaqGM:CDLX

Capitalización de mercado: US$38.1m

Cardlytics (CDLX) Resumen de Acciones

Cardlytics, Inc. explota una plataforma publicitaria en Estados Unidos y el Reino Unido. Saber más

Análisis fundamental de CDLX
Puntuación del snowflake
Valoración2/6
Crecimiento futuro0/6
Rendimiento pasado0/6
Salud financiera2/6
Dividendos0/6

CDLX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Competidores de Cardlytics, Inc.

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Cardlytics
Precios históricos de las acciones
Precio actual de la acciónUS$0.72
Máximo en las últimas 52 semanasUS$3.28
Mínimo de 52 semanasUS$0.57
Beta0.69
Cambio en 1 mes-22.49%
Variación en 3 meses-18.28%
Cambio de 1 año-61.45%
Variación en 3 años-87.01%
Variación en 5 años-99.33%
Variación desde la OPV-94.61%

Noticias y actualizaciones recientes

Actualización de narrativa May 15

CDLX: Reset Guidance And Banking Shifts Will Drive Future Repricing Potential

Narrative update on Cardlytics The analyst price target for Cardlytics has shifted from $1.25 to $1.50, with analysts pointing to updated assumptions around discount rates, revenue trends, margins, and future P/E after recent resets in expectations following Q4 results, Q1 guidance, and the impact of the BofA exit and Bridg divestiture. Analyst Commentary Recent research has centered on how Cardlytics should be valued after its Q4 results, Q1 guidance, and the announced BofA exit and Bridg divestiture.
Artículo de análisis May 11

Cardlytics, Inc. (NASDAQ:CDLX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Cardlytics, Inc. ( NASDAQ:CDLX ) just released its latest first-quarter results and things are looking bullish...
Actualización de narrativa May 01

CDLX: Reset Expectations And Banking Partner Shifts Will Drive Future Repricing

Analysts have nudged Cardlytics' average price target lower to about $1, with cuts from $2 to $1 and from $1.50 to $1.25. These changes reflect updated views after Q4 results, Q1 guidance, and the expected impact of the BofA exit and Bridg divestiture.

Recent updates

Actualización de narrativa May 15

CDLX: Reset Guidance And Banking Shifts Will Drive Future Repricing Potential

Narrative update on Cardlytics The analyst price target for Cardlytics has shifted from $1.25 to $1.50, with analysts pointing to updated assumptions around discount rates, revenue trends, margins, and future P/E after recent resets in expectations following Q4 results, Q1 guidance, and the impact of the BofA exit and Bridg divestiture. Analyst Commentary Recent research has centered on how Cardlytics should be valued after its Q4 results, Q1 guidance, and the announced BofA exit and Bridg divestiture.
Artículo de análisis May 11

Cardlytics, Inc. (NASDAQ:CDLX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Cardlytics, Inc. ( NASDAQ:CDLX ) just released its latest first-quarter results and things are looking bullish...
Actualización de narrativa May 01

CDLX: Reset Expectations And Banking Partner Shifts Will Drive Future Repricing

Analysts have nudged Cardlytics' average price target lower to about $1, with cuts from $2 to $1 and from $1.50 to $1.25. These changes reflect updated views after Q4 results, Q1 guidance, and the expected impact of the BofA exit and Bridg divestiture.
Actualización de narrativa Apr 17

CDLX: Reset Guidance And BofA Exit Will Drive Upside Potential

Narrative Update on Cardlytics Analysts have cut their Cardlytics price targets to a range of about $1 to $1.25, citing Q1 guidance that resets expectations following the Bank of America exit and Bridg divestiture and leaves the stock in what they describe as "show me" territory. Analyst Commentary Recent research updates underline that Q1 guidance and the effects of the Bank of America exit and Bridg divestiture are central to how analysts are framing Cardlytics today.
Actualización de narrativa Apr 03

CDLX: Reset Expectations And Partner Changes Will Shape Future Repricing

Analysts have trimmed Cardlytics' implied fair value from about $1.29 to roughly $1.04. This reflects recent price target cuts to $1 and $1.25 as they factor in softer revenue expectations and the impact of the BofA exit and Bridg divestiture.
Actualización de narrativa Mar 20

CDLX: Reset Guidance And One Bank Exit Will Define Upside Potential

Narrative update on Cardlytics Analysts have trimmed Cardlytics' implied fair value from about $2.00 to roughly $1.25, reflecting lower price targets around $1.00 to $1.25 after Q1 guidance reset expectations for revenue trends, margins and future P/E as the business adjusts to the BofA exit and Bridg divestiture. Analyst Commentary Recent Street research has centered on recalibrated price targets around Q1 guidance and the operational impact of the BofA exit and Bridg divestiture.
Actualización de narrativa Mar 06

CDLX: Reset Expectations And CFO Return Will Support Future Rerating

Analysts have trimmed their Cardlytics price target from $1.50 to $1.25, reflecting updated assumptions around fair value, revenue trends, and profitability following recent guidance resets and business changes. Analyst Commentary Recent commentary around the reduced US$1.25 price target centers on how quickly Cardlytics can adjust to its updated outlook and business mix after the Q1 guidance reset, the BofA exit, and the Bridg divestiture.
Artículo de análisis Jan 08

Cardlytics, Inc. (NASDAQ:CDLX) Stock Catapults 30% Though Its Price And Business Still Lag The Industry

Those holding Cardlytics, Inc. ( NASDAQ:CDLX ) shares would be relieved that the share price has rebounded 30% in the...
Seeking Alpha Oct 06

Cardlytics: Debt Overhang Casts Shadow On Upside

Summary Cardlytics is dealing with a significant headwind in Q3 due to restrictions from its largest bank partner. CDLX sold off sharply following Q2 results, but has since rallied following a bullish report from Citron Research. Management is targeting positive FCF through growth with its newest large bank partner while also substantially lowering operating expenses. Debt remains the biggest risk, though the earliest maturity is not until April 2028. I remain cautious until I see evidence of sequential growth and improving cash burn. Read the full article on Seeking Alpha
Actualización de narrativa Aug 08

Bank Partnerships And Data-Driven Marketing Will Shape Future Markets

The notable downward revision in Cardlytics’ price target reflects sharply reduced revenue growth forecasts and a higher discount rate, resulting in a new consensus fair value of $2.10. What's in the News Cardlytics provided Q3 2025 revenue guidance of $52.2 million to $58.2 million.
Artículo de análisis Jul 23

Revenues Tell The Story For Cardlytics, Inc. (NASDAQ:CDLX) As Its Stock Soars 64%

Cardlytics, Inc. ( NASDAQ:CDLX ) shares have continued their recent momentum with a 64% gain in the last month alone...
Artículo de análisis Jul 05

Is Cardlytics (NASDAQ:CDLX) Using Debt Sensibly?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Artículo de análisis May 29

Cardlytics, Inc. (NASDAQ:CDLX) Soars 30% But It's A Story Of Risk Vs Reward

Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders are no doubt pleased to see that the share price has bounced 30% in the...
Artículo de análisis Apr 07

Why Investors Shouldn't Be Surprised By Cardlytics, Inc.'s (NASDAQ:CDLX) 30% Share Price Plunge

Unfortunately for some shareholders, the Cardlytics, Inc. ( NASDAQ:CDLX ) share price has dived 30% in the last thirty...
User avatar
Nueva narrativa Apr 03

US Neobank And Taiwan Office Will Unlock New Markets

Expansion into new sectors and partnerships with financial institutions and neobanks is expected to diversify the customer base and boost revenue.
Artículo de análisis Mar 11

Cardlytics (NASDAQ:CDLX) Has Debt But No Earnings; Should You Worry?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Artículo de análisis Feb 21

Revenues Tell The Story For Cardlytics, Inc. (NASDAQ:CDLX)

It's not a stretch to say that Cardlytics, Inc.'s ( NASDAQ:CDLX ) price-to-sales (or "P/S") ratio of 0.5x right now...
Seeking Alpha Feb 13

Cardlytics: Short-Term Headwinds Drive Long-Term Success

Summary Cardlytics, Inc. offers an asymmetric investment opportunity for those who can handle stock price volatility and slow business progress. Recent issues with ad deliveries have impacted revenue and market sentiment but positioned the company for long-term success. The shift to engagement-based pricing is expected to drive broader platform adoption. Trading at just 0.51x P/S and 1.10x EV/Revenue, Cardlytics presents significant upside potential from current valuations. Amex Partnership could add $600 million in market value based on $35 million in incremental EBITDA for 2025. Read the full article on Seeking Alpha
Artículo de análisis Jan 10

At US$3.35, Is It Time To Put Cardlytics, Inc. (NASDAQ:CDLX) On Your Watch List?

Cardlytics, Inc. ( NASDAQ:CDLX ), might not be a large cap stock, but it saw significant share price movement during...
Seeking Alpha Dec 07

Cardlytics Continues Revenue Contraction Amid Worsening Economics

Summary Cardlytics, Inc. beat revenue and earnings estimates, but faces declining unit economics and revenue stabilization challenges. The AdTech market is projected to grow significantly, yet CDLX struggles with delivery inefficiencies, declining ARPU, and advertiser hesitancy, impacting its financial performance. Recent financial trends show falling revenue, negative operating income, and high stock-based compensation, with significant cash burn and a 52.1% stock price decline over the past year. Management's turnaround efforts may take several quarters, with increased R&D spending expected to further negatively affect operating results. My outlook on CDLX is to sell. Read the full article on Seeking Alpha
Artículo de análisis Nov 23

Estimating The Intrinsic Value Of Cardlytics, Inc. (NASDAQ:CDLX)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Cardlytics fair value estimate is US$3.50 Current share price...
Artículo de análisis Nov 05

After Leaping 27% Cardlytics, Inc. (NASDAQ:CDLX) Shares Are Not Flying Under The Radar

Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...
Artículo de análisis Oct 15

Is Cardlytics (NASDAQ:CDLX) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha Sep 17

Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating)

Summary Shares have fallen nearly 50% since the Q2 earnings report, which came in well below management’s guidance. With Q3 guidance pointing to further weakness, the company’s financial health hinges on management’s execution towards solving the ongoing issues on its ads platform. Assuming no additional setbacks, the company should return to growth next year and generate positive FCF. While risks remain high, the current valuation is undemanding, leading me to maintain a Neutral rating. Read the full article on Seeking Alpha
Artículo de análisis Aug 09

Cardlytics, Inc.'s (NASDAQ:CDLX) 63% Share Price Plunge Could Signal Some Risk

Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders that were waiting for something to happen have been dealt a blow with a...
Seeking Alpha Jul 02

Cardlytics: Has Multiple Potential Growth Levers, But Persistent Risks Remain

Summary Cardlytics shares have declined significantly after Q1 earnings came in below management’s guidance. Key metrics show that the business is performing well. Recent steps taken by management have extended its debt until 2029, leaving the company in a more stable financial position. CDLX has multiple growth levers and significant risks that investors should consider. Read the full article on Seeking Alpha
Artículo de análisis May 31

Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

The Cardlytics, Inc. ( NASDAQ:CDLX ) share price has softened a substantial 30% over the previous 30 days, handing back...
Seeking Alpha Apr 17

The Power Of Cardlytics' Data Partnerships Including Bank of America

Summary Cardlytics recently appointed Liane Hornsey to its Board of Directors, which could attract new investors and accelerate hiring and productivity. The company offers a suite of solutions for advertising, marketing, and customer engagement through its own mobile application and partnerships with financial institutions. Future growth projects, synergies, database integration, and new partnerships have the potential to drive net sales growth and increase investor attention. Read the full article on Seeking Alpha
Artículo de análisis Apr 10

Cardlytics, Inc.'s (NASDAQ:CDLX) 81% Jump Shows Its Popularity With Investors

Despite an already strong run, Cardlytics, Inc. ( NASDAQ:CDLX ) shares have been powering on, with a gain of 81% in the...
Seeking Alpha Feb 16

Cardlytics: Good Prospects But Macro Uncertain

Summary Cardlytics has access to 50% of card swipe data through its relationships with major US consumer banks. The company's acquisitions of Dosh and Bridg have strengthened and diversified its platform. The impact of macroeconomic factors on consumer spending and advertising budgets may constrain Cardlytics' growth in the short to medium term. Read the full article on Seeking Alpha
Artículo de análisis Jan 18

Cardlytics, Inc.'s (NASDAQ:CDLX) 29% Share Price Plunge Could Signal Some Risk

Unfortunately for some shareholders, the Cardlytics, Inc. ( NASDAQ:CDLX ) share price has dived 29% in the last thirty...
Artículo de análisis Jan 04

Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Rentabilidad de los accionistas

CDLXUS MediaMercado US
7D20.9%-0.8%1.2%
1Y-61.5%-16.3%28.7%

Rentabilidad vs. Industria: Los resultados de CDLX fueron inferiores a los de la industria US Media, que obtuvo un rendimiento del -16.3% el año pasado.

Rentabilidad vs. Mercado: CDLX obtuvo unos resultados inferiores a los del mercado US, que fueron del 28.7% el año pasado.

Volatilidad de los precios

Is CDLX's price volatile compared to industry and market?
CDLX volatility
CDLX Average Weekly Movement14.9%
Media Industry Average Movement9.2%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Precio estable de las acciones: El precio de las acciones de CDLX ha sido volátil durante los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de CDLX ha disminuido de 22% a 15% en el último año, pero sigue siendo superior al 75% de los valores de US.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
2008275Amit Guptawww.cardlytics.com

Cardlytics, Inc. opera una plataforma publicitaria en Estados Unidos y el Reino Unido. La empresa ofrece la plataforma Cardlytics, un canal propio de publicidad bancaria nativa que permite a los profesionales del marketing llegar a los clientes a través de canales digitales, como Internet, aplicaciones móviles, correo electrónico y diversas notificaciones en tiempo real; y la plataforma Bridg, una plataforma de datos de clientes que utiliza datos de puntos de venta de socios de datos comerciales, incluidos datos de compra a nivel de producto para permitir a los profesionales del marketing realizar análisis y marketing de fidelización específico, así como medir el impacto de su marketing. Cardlytics, Inc. se constituyó en 2008 y tiene su sede en Atlanta, Georgia.

Resumen de fundamentos de Cardlytics, Inc.

¿Cómo se comparan los beneficios e ingresos de Cardlytics con su capitalización de mercado?
Estadísticas fundamentales de CDLX
Capitalización bursátilUS$38.14m
Beneficios(TTM)-US$106.97m
Ingresos (TTM)US$211.16m
0.2x
Ratio precio-ventas (PS)
-0.4x
Ratio precio-beneficio (PE)

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de CDLX
IngresosUS$211.16m
Coste de los ingresosUS$110.95m
Beneficio brutoUS$100.21m
Otros gastosUS$207.18m
Beneficios-US$106.97m

Últimos beneficios comunicados

Mar 31, 2026

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)-1.94
Margen bruto47.46%
Margen de beneficio neto-50.66%
Ratio deuda/patrimonio-5,101.2%

¿Cómo se ha desempeñado CDLX a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/26 02:58
Precio de las acciones al final del día2026/05/26 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Cardlytics, Inc. está cubierta por 12 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Omar DessoukyBofA Global Research
Jason KreyerCraig-Hallum Capital Group LLC
Robert CoolbrithEvercore ISI